Guangzhou Baiyunshan Pharmaceutical Holdings (00874) reported a net profit attributable to shareholders of approximately RMB2.492 billion for the first three quarters, down 24.73% year on year.
Baiyunshan (00874) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB62.076 billion, up 0.76% year on year; net profit attributable to shareholders of the listed company of approximately RMB2.492 billion, down 24.73% year on year; and basic earnings per share of RMB1.533.
Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB62.076 billion, up 0.76% year on year; net profit attributable to shareholders of the listed company of approximately RMB2.492 billion, down 24.73% year on year; and basic earnings per share of RMB1.533.
Related Articles
GEEKPLUS-W (02590) repurchased 100,000 shares for HK$653,600 on October 28.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-8046 tablets approved to initiate clinical trials
COSCO SHIPPING Energy Transportation (01138): Hainan Zhaogang plans to build an ethylene carrier for RMB335 million
GEEKPLUS-W (02590) repurchased 100,000 shares for HK$653,600 on October 28.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-8046 tablets approved to initiate clinical trials
COSCO SHIPPING Energy Transportation (01138): Hainan Zhaogang plans to build an ethylene carrier for RMB335 million
